Stockwatch: A painful walking through approval probability
This article was originally published in Scrip
After sinking over $100 million into the company, investors now want to know whether the US FDA will allow Sarepta Therapeutics to file for the fast-track approval of a drug for Duchenne muscular dystrophy (DMD) on a dataset covering just eight patients. The important information, however, is not about filing but about the chances of approval, and its timing. Sarepta has said little about its trial data, but what it has said shows that the data is probably fragile, at best.
You may also be interested in...
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.
Pharmaceutical shares are stronger than most as world stock markets dive downwards, but they are not immune to the coronavirus fallout. The effects will be felt by biopharma companies across many areas of their activity.